The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pembrolizumab in microsatellite instability high (MSI-H)/mismatch repair deficient (dMMR) cancers: Updated analysis from phase 2 KEYNOTE-158 study.
 
Michele Maio
Stock and Other Ownership Interests - Theravance
Honoraria - Alfasigma; Amgen; AstraZeneca; Bristol-Myers Squibb; Merck; MSD; Pierre Fabre; Roche
Consulting or Advisory Role - Alfasigma; AstraZeneca; Bristol-Myers Squibb; Merck; MSD; Pierre Fabre; Roche
Patents, Royalties, Other Intellectual Property - DNA Hypomethylating agents for cancer therapy
Travel, Accommodations, Expenses - Alfasigma; Amgen; AstraZeneca; Bristol-Myers Squibb; Merck; MSD; Pierre Fabre; Roche
 
Paolo Antonio Ascierto
Stock and Other Ownership Interests - PrimeVax
Consulting or Advisory Role - 4SC; Alkermes; Array BioPharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Idera; Immunocore; Incyte; Italfarmaco; Lunaphore Technologies; MedImmune; Merck Serono; Merck Sharp & Dohme; Nektar; Nouscom; Novartis; OncoSec; Pfizer; Pierre Fabre; Regeneron; Roche/Genentech; Sandoz; Sanofi; Seagen; Sun Pharma; Takis Biotech; Ultimovacs
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Ludmila Manzyuk
No Relationships to Disclose
 
Daniel Motola-Kuba
Research Funding - Amgen; AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Janssen; Lilly; Merck Sharp & Dohme; Novartis; Roche/Genentech
 
Nicolas Penel
Research Funding - Bayer (Inst); Bayer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Astellas Pharma; Janssen-Cilag
Other Relationship - PharmaMar
 
Philippe A. Cassier
Honoraria - Amgen; AstraZeneca; Merck Serono; Novartis; Roche/Genentech
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); GlaxoSmithKline (Inst); Innate Pharma (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Plexxikon (Inst); Roche/Genentech (Inst); Taiho Pharmaceutical (Inst); Toray Industries (Inst); Transgene (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Netris Pharma; Novartis; Roche
 
Giovanni Bariani
Consulting or Advisory Role - Libbs; Libbs
Research Funding - Bristol-Myers Squibb; Mabxience; Merck Sharp & Dohme
 
Ana De Jesus-Acosta
Consulting or Advisory Role - Merck
Research Funding - AstraZeneca (Inst); Merck (Inst)
 
Toshihiko Doi
Honoraria - Abbvie; Astellas Pharma; Bristol-Myers Squibb Japan; Oncolys BioPharma; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Abbvie; Amgen; Bayer; Boehringer Ingelheim; Daiichi Sankyo; MSD; Novartis; Otsuka; Rakuten Medical; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda
Research Funding - Abbvie (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Quintiles (Inst); Sumitomo Group (Inst); Taiho Pharmaceutical (Inst)
 
Federico Longo
Honoraria - Amgen; Bayer; Bristol-Myers Squibb; Celgene; Ferrer; Lilly; Merck; MSD; Roche; Sanofi; SERVIER
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Lilly; MSD; Roche; SERVIER
Travel, Accommodations, Expenses - Amgen; Bayer; Bristol-Myers Squibb; Celgene; Ferrer; Lilly; Merck; MSD; Roche; Sanofi; SERVIER
 
Wilson H. Miller
Honoraria - Amgen; Bristol Myers Squibb Foundation; EMD Serono; GlaxoSmithKline; Merck; Mylan; Novartis; Roche
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; EMD Serono; GlaxoSmithKline; Merck; Mylan; Novartis; Roche
Research Funding - Amgen (Inst); Array BioPharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Canada Research Society (Inst); Canada Research Society (Inst); Canadian Cancer Society Research Institute (CCSRI) (Inst); Canadian Institutes of Health Research (CIHR) (Inst); Esperas Pharma (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Incyte (Inst); MedImmune (Inst); Merck (Inst); Merck (Inst); MethylGene (Inst); MethylGene (Inst); Mimic Technologies (Inst); Novartis (Inst); Ocellaris Pharma (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst); Samuel Waxman Cancer Research Foundation (Inst); Sanofi (Inst); TERRY FOX RESEARCH INSTITUTE (Inst)
 
Do-Youn Oh
Consulting or Advisory Role - ASLAN Pharmaceuticals; AstraZeneca; Basilea; Bayer; BeiGene; Celgene; Genentech/Roche; Halozyme; Merck Serono; Novartis; Taiho Pharmaceutical; Zymeworks
Research Funding - Array BioPharma; AstraZeneca; BeiGene; Lilly; MSD; Novartis; SERVIER
 
Maya Gottfried
No Relationships to Disclose
 
Ruixue Wang
Employment - MSD
Stock and Other Ownership Interests - Merck
 
Fan Jin
Employment - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck; Merck
 
Kevin Glen Norwood
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck
 
Aurelien Marabelle
Stock and Other Ownership Interests - Centessa Pharmaceuticals; Centessa Pharmaceuticals (Inst); HiFiBiO Therapeutics; PEGASCY; PEGASCY (Inst); Shattuck Labs
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; Oncovir
Consulting or Advisory Role - AstraZeneca; Centessa Pharmaceuticals; Eisai; HiFiBiO Therapeutics; ImCheck therapeutics; Innate Pharma; Lytix Biopharma; MedinCell; MSD; OSE Immunotherapeutics; Pierre Fabre; Redx Pharma; Roche; SERVIER; Sotio
Speakers' Bureau - BMS
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Transgene (Inst)
Patents, Royalties, Other Intellectual Property - monoclonal antibodies against CD81 (Stanford University)
Travel, Accommodations, Expenses - AstraZeneca; MSD